EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis
- DOI
- 10.1186/s12885-026-16193-x
- Published
- 2026-05-20
- Container
- BMC Cancer
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12885-026-16193-x,
title = {EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis},
author = {Fei Qi and Yuzhu Chen and Yi Han and Peng Jiang and Siyu Lei and Xingyu Du and Yuan Gao and Fan Zhang and Juan Du and Hongxia Li and Tongmei Zhang},
year = {2026},
journal = {BMC Cancer},
doi = {10.1186/s12885-026-16193-x},
url = {https://doi.org/10.1186/s12885-026-16193-x}
}RIS
TY - JOUR TI - EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis AU - Fei Qi AU - Yuzhu Chen AU - Yi Han AU - Peng Jiang AU - Siyu Lei AU - Xingyu Du AU - Yuan Gao AU - Fan Zhang AU - Juan Du AU - Hongxia Li AU - Tongmei Zhang PY - 2026 JO - BMC Cancer DO - 10.1186/s12885-026-16193-x UR - https://doi.org/10.1186/s12885-026-16193-x ER -
APA
Qi, F., Chen, Y., Han, Y., Jiang, P., Lei, S., Du, X., Gao, Y., Zhang, F., Du, J., Li, H., & Zhang, T. (2026). EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16193-x
Source records
- crossref · retrieved 2026-09-27T14:05:33.244Z